Cardiff Lexington Corporation CDIX

Q2 FY2026 · ended Jun 30, 2026 · Revenue $2.16M, -22.6% YoY · Filed Aug 12, 2026

Cardiff Lexington Corporation (CDIX) files with the SEC under industry code 8011, Services-Offices & Clinics of Doctors of Medicine. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $2.2 million and a net loss of $2.5 million. As of Jun 30, 2026 it held $217,654 in cash and investments and $22.8 million in total debt.

Revenue
$2.16M
-22.6% vs year-ago quarter
Net income
$-2.48M
-102.1% vs year-ago quarter
Operating cash flow
$-651,919
-3796.7% vs prior quarter
Free cash flow
—
EPS
$-0.18
+21.7% vs prior quarter
Dividend per share
None
Shares outstanding
15.64M
-20.6% vs year-ago quarter
Net cash
$-22.62M
Q2 FY2026
Operating margin
-10.9%
TTM

Company profile

Industry
Services-Offices & Clinics of Doctors of Medicine (SIC 8011)
Listed as
CDIX (OTC)
Fiscal year ends
December 31
Incorporated in
FL
Headquarters
Lexington, KY
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
811222
Former names
CARDIFF INTERNATIONAL INC (until Jan 26, 2018)

Other Services-Offices & Clinics of Doctors of Medicine companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Line
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Revenue
$2.2M
$2.2M
$2.8M
$3.1M
$2.8M
Operating income
-$544,643
-$511,159
-$696,304
$643,279
$609,677
Net income
-$2.5M
-$3.1M
-$2.7M
-$1.1M
-$1.2M
Diluted EPS
-$0.18
-$0.23
—
—
—
Operating cash flow
-$651,919
-$16,730
—
—
—
Total assets
$30.7M
$30.3M
$29.1M
$27.6M
$26.5M
Total liabilities
$27.1M
$24.6M
$26.0M
$22.6M
$20.5M
Stockholders' equity
$1.8M
$3.9M
-$2.5M
-$364,430
$753,604
Cash and investments
$217,654
$683,507
$318,535
$232,033
$559,715
Total debt
$22.8M
$161,303
$18.8M
$15.4M
$13.5M

Recent SEC filings

Recent SEC filings
Form Description Filed Period
8-K Current report
Other events
Sep 24, 2026 Sep 24, 2026
8-K Current report
Change to shareholder rights, Bylaw or fiscal year change
Sep 4, 2026 Aug 31, 2026
10-Q Quarterly report Aug 12, 2026 Jun 30, 2026
8-K Current report
Material agreement
Jun 11, 2026 Jun 5, 2026
10-Q Quarterly report May 13, 2026 Mar 31, 2026
10-K Annual report Mar 10, 2026 Dec 31, 2025

Source: SEC EDGAR filings. This is company-reported data, not investment advice.